Circulating renin-angiotensin-aldosterone system markers in cats with non-hypertensive chronic kidney disease or systemic arterial hypertension.

Clinical Context

Peer-reviewed veterinary literature continues to shape everyday decision-making for feline patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.

What the Study Evaluated

A study published in Journal of veterinary internal medicine in 2026 evaluated circulating renin-angiotensin-aldosterone system markers in cats with non-hypertensive chronic kidney disease or systemic arterial hypertension..

Key Findings

Information on the classical and alternative circulating renin-angiotensin-aldosterone systems (RAAS) in cats with non-hypertensive chronic kidney disease (NHT-CKD) or systemic arterial hypertension (SAH) is limited. Age and diet affect the RAAS. To compare serum equilibrium concentrations of angiotensin peptides and aldosterone in healthy cats and cats with NHT-CKD or untreated SAH, and to evaluate changes in these concentrations in hypertensive cats administered amlodipine. Client-owned cats with NHT-CKD (serum creatinine ≥ 1.6 mg/dL, systolic blood pressure [SBP] < 160 mmHg; n = 17), SAH (SBP ≥ 160 mmHg or ≥ 150 mmHg with hypertensive...

Why It Matters for Veterinary Professionals

For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for feline patients.

Practical Interpretation

The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.

Clinical Takeaway

Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.

Read the full article here.